Welcome to our dedicated page for Tactile Systems SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tactile Systems Technology, Inc. (Tactile Medical) SEC filings page for ticker TCMD provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology company incorporated in Delaware, Tactile Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K under Commission File Number 001-37799.
Through these filings, investors can review detailed information on Tactile Medical’s business, including its focus on at-home therapies for lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. Periodic reports describe revenue from sales and rentals of the lymphedema product line and sales of the airway clearance product line, along with discussions of gross margin, operating expenses, net income or loss and non-GAAP measures such as Adjusted EBITDA as defined by the company.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and the authorization of share repurchase programs for the company’s common stock. These filings may include information on the size and duration of repurchase authorizations and the company’s intention to fund them from cash and future cash flows.
On Stock Titan, TCMD filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight key points from lengthy documents, helping users quickly understand topics such as segment performance, capital allocation decisions and risk factor discussions without reading every page. Users can also review insider-related filings, including Forms 3, 4 and 5, to track equity transactions by directors and officers, and proxy statements on Schedule 14A for information on governance and executive compensation.
Whether you are analyzing Tactile Medical’s financial history, monitoring new 8-K disclosures or looking for details on its at-home therapy business, this page centralizes the company’s official SEC filings with concise AI-generated insights.
Tactile Systems Technology chief executive officer Sheri Louise Dodd reported an equity award on Common Stock. She acquired 48,672 restricted stock units at a stated price of $0.00 per share as a grant or award, bringing her directly held stake to 222,151 shares after the transaction.
The RSUs vest in three equal annual installments, with one-third becoming available on each of the first three anniversaries of the grant date. This structure ties the CEO’s compensation to continued service and the company’s long-term performance.
Burns Kristie reported acquisition or exercise transactions in this Form 4 filing.
Tactile Systems Technology senior vice president Kristie Burns reported an equity award of 6,194 shares of common stock in the form of restricted stock units. The RSUs vest in three equal installments on each of the first three anniversaries of the grant date. After this award, she directly holds 78,595 shares of common stock, reflecting her updated ownership position in the company.
Birkemeyer Elaine M. reported acquisition or exercise transactions in this Form 4 filing.
Tactile Systems Technology chief financial officer Elaine M. Birkemeyer received a grant of 23,008 shares of common stock in the form of restricted stock units at a stated price of
The RSUs vest over three years, with one-third of the units vesting on each of the first three anniversaries of the grant date, meaning the compensation is spread over time and depends on continued service.
Kristie Burns submitted a Form 144 notice to sell common stock. The filing lists 4,439 shares tied to restricted stock vesting on
Tactile Systems Technology, Inc. reports full-year 2025 results and provides a detailed overview of its medical technology business focused on at-home treatment of chronic diseases. The company generated $329.5 million in revenue and $19.1 million in net income for 2025, with revenue growing 12% year over year.
Lymphedema products, including Flexitouch Plus, Entre Plus and Nimbl, produced $278.4 million or 84% of 2025 revenue, while the AffloVest airway clearance product line contributed $51.1 million or 16%. Tactile highlights broad U.S. reimbursement coverage, in‑network payer contracts covering about 278 million lives, and a largely direct-to-patient model for lymphedema alongside a DME distribution model for AffloVest.
The filing emphasizes extensive clinical evidence supporting Flexitouch, Nimbl and AffloVest, ongoing R&D investment of $8.5 million in 2025, and a sizable commercial organization with 166 account managers and 185 specialists as of December 31, 2025. Management also outlines significant market opportunities in lymphedema, chronic venous insufficiency and bronchiectasis, while detailing the regulatory, reimbursement and fraud-and-abuse frameworks governing its operations.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to
The company ended 2025 with
Cadian Capital filed an amended Schedule 13G/A showing passive ownership in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Cadian Capital Management, its general partner, and Eric Bannasch were deemed to beneficially own 1,084,094 shares, or about 4.9% of the outstanding common stock.
All shares are held by advisory clients of Cadian Capital Management, over which the adviser has shared voting and investment power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Paradigm Capital Management, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Tactile Systems Technology, Inc. common stock. As of December 31, 2025, Paradigm beneficially owned 736,599 shares, representing 3.29% of the company’s common stock, with sole voting and dispositive power.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Tactile Systems Technology.